Tue, 30 June 2015
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
Direct download: GRACEcast-336_ASCO_2015_SCLC_Patients_Immunotherapy_Benefit.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT